Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (141-150 of 317) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2013
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)Sander Kelderman, Monique K van der Kooij, Alfons J M van den Eertwegh, et al.
Oncoimmunology|February 7, 2019
A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanomaThijs T Wind, Mathilde Jalving, Jacco J de Haan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanomaJudith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Cancer Immunology, Immunotherapy : CII|August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infectionsC Schmitt, E P Hoefsmit, T Fangmeier, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2015
Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell ReceptorJoost H van den Berg, Raquel Gomez-Eerland, Bart van de Wiel, et al.
Pageof 32

Showing results (141-150 of 317) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2013
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)Sander Kelderman, Monique K van der Kooij, Alfons J M van den Eertwegh, et al.
Oncoimmunology|February 7, 2019
A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanomaThijs T Wind, Mathilde Jalving, Jacco J de Haan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanomaJudith M Versluis, Irene L M Reijers, Elisa A Rozeman, et al.
Cancer Immunology, Immunotherapy : CII|August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infectionsC Schmitt, E P Hoefsmit, T Fangmeier, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2015
Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell ReceptorJoost H van den Berg, Raquel Gomez-Eerland, Bart van de Wiel, et al.
Pageof 32